Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laurie, J. A.
Right arrow Articles by Malliard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laurie, J. A.
Right arrow Articles by Malliard, J.

Journal of Clinical Oncology, Vol 7, 1447-1456, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

JA Laurie, CG Moertel, TR Fleming, HS Wieand, JE Leigh, J Rubin, GW McCormack, JB Gerstner, JE Krook and J Malliard
Grand Forks Clinic, Ltd, ND.

A total of 401 eligible patients with resected stages B and C colorectal carcinoma were randomly assigned to no-further therapy or to adjuvant treatment with either levamisole alone, 150 mg/d for 3 days every 2 weeks for 1 year, or levamisole plus fluorouracil (5-FU), 450 mg/m2/d intravenously (IV) for 5 days and beginning at 28 days, 450 mg/m2 weekly for 1 year. Levamisole plus 5-FU, and to a lesser extent levamisole alone, reduced cancer recurrence in comparison with no adjuvant therapy. These differences, after correction for imbalances in prognostic variables, were only suggestive for levamisole alone (P = .05) but quite significant for levamisole plus 5-FU (P = .003). Whereas both treatment regimens were associated with overall improvements in survival, these improvements reached borderline significance only for stage C patients treated with levamisole plus 5-FU (P = .03). Therapy was clinically tolerable with either regimen and severe toxicity was uncommon. These promising results have led to a large national intergroup confirmatory trial currently in progress.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. Zlobec, L. M. Terracciano, and A. Lugli
Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes
Clin. Cancer Res., June 15, 2008; 14(12): 3792 - 3797.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
T. R Fleming, K. Sharples, J. McCall, A. Moore, A. Rodgers, and R. Stewart
Maintaining confidentiality of interim data to enhance trial integrity and credibility
Clinical Trials, April 1, 2008; 5(2): 157 - 167.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
C. J. Bradley, C. W. Given, B. Dahman, and T. L. Fitzgerald
Adjuvant Chemotherapy After Resection in Elderly Medicare and Medicaid Patients With Colon Cancer
Arch Intern Med, March 10, 2008; 168(5): 521 - 529.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Berglund, B. Cedermark, and B. Glimelius
Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
Ann. Onc., February 1, 2008; 19(2): 400 - 402.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 BiostatisticsHome page
Y. Shen and Y. Cheng
Adaptive design: estimation and inference with censored data in a semiparametric model
Biostat., April 1, 2007; 8(2): 306 - 322.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
M J White, R L O'Gorman, E M Charles-Edwards, P A Kane, J B Karani, M O Leach, and J J Totman
Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI
Br. J. Radiol., February 1, 2007; 80(950): 113 - 120.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. R. Smalley, J. K. Benedetti, S. K. Williamson, J. M. Robertson, N. C. Estes, T. Maher, B. Fisher, T. A. Rich, J. A. Martenson, J. W. Kugler, et al.
Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144
J. Clin. Oncol., August 1, 2006; 24(22): 3542 - 3547.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J M Carethers
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
Gut, June 1, 2006; 55(6): 759 - 761.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Goldberg, D. Niedzwiecki, M. Bertagnolli, A. W. Blackstock, J. E. Tepper, and R. J. Mayer
Cancer and leukemia group B gastrointestinal cancer committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3589s - 3595s.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. R. Grann and F. M. Muggia
Completion rates of adjuvant chemotherapy for colon cancer: a historical perspective.
J Natl Cancer Inst, May 3, 2006; 98(9): 570 - 571.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. A. Dobie, L.-M. Baldwin, J. A. Dominitz, B. Matthews, K. Billingsley, and W. Barlow
Completion of therapy by Medicare patients with stage III colon cancer.
J Natl Cancer Inst, May 3, 2006; 98(9): 610 - 619.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Y.-A. Park, K. Y. Lee, N. K. Kim, S. H. Baik, S. K. Sohn, and C. W. Cho
Prognostic Effect of Perioperative Change of Serum Carcinoembryonic Antigen Level: A Useful Tool for Detection of Systemic Recurrence in Rectal Cancer
Ann. Surg. Oncol., May 1, 2006; 13(5): 645 - 650.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. M. Jessup, A. Stewart, F. L. Greene, and B. D. Minsky
Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation
JAMA, December 7, 2005; 294(21): 2703 - 2711.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
E. Van Cutsem and F. Costa
Progress in the Adjuvant Treatment of Colon Cancer: Has It Influenced Clinical Practice?
JAMA, December 7, 2005; 294(21): 2758 - 2760.
[Full Text] [PDF]

Home page
 JCOHome page
D. G. Haller, P. J. Catalano, J. S. Macdonald, M. A. O'Rourke, M. S. Frontiera, D. V. Jackson, and R. J. Mayer
Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089
J. Clin. Oncol., December 1, 2005; 23(34): 8671 - 8678.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Sargent, H. S. Wieand, D. G. Haller, R. Gray, J. K. Benedetti, M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, G. Francini, et al.
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
J. Clin. Oncol., December 1, 2005; 23(34): 8664 - 8670.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al.
Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment
J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Alhopuro, H. Alazzouzi, H. Sammalkorpi, V. Davalos, R. Salovaara, A. Hemminki, H. Jarvinen, J.-P. Mecklin, S. Schwartz Jr., L. A. Aaltonen, et al.
SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer
Clin. Cancer Res., September 1, 2005; 11(17): 6311 - 6316.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren
Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information
J. Clin. Oncol., August 20, 2005; 23(24): 5628 - 5634.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Scott, F.-T. Lee, R. Jones, W. Hopkins, D. MacGregor, J. S. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, et al.
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
Clin. Cancer Res., July 1, 2005; 11(13): 4810 - 4817.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Kidd, J. Yu, X. Li, W. D. Shannon, M. A. Watson, and H. L. McLeod
Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer
Clin. Cancer Res., April 1, 2005; 11(7): 2612 - 2619.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Poplin, J. K. Benedetti, N. C. Estes, D. G. Haller, R. J. Mayer, R. M. Goldberg, G. R. Weiss, S. E. Rivkin, and J. S. Macdonald
Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer
J. Clin. Oncol., March 20, 2005; 23(9): 1819 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Figueredo, M. L. Charette, J. Maroun, M. C. Brouwers, and L. Zuraw
Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group
J. Clin. Oncol., August 15, 2004; 22(16): 3395 - 3407.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. B. Benson III, D. Schrag, M. R. Somerfield, A. M. Cohen, A. T. Figueredo, P. J. Flynn, M. K. Krzyzanowska, J. Maroun, P. McAllister, E. Van Cutsem, et al.
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
J. Clin. Oncol., August 15, 2004; 22(16): 3408 - 3419.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. L. Gunderson, D. J. Sargent, J. E. Tepper, N. Wolmark, M. J. O'Connell, M. Begovic, C. Allmer, L. Colangelo, S. R. Smalley, D. G. Haller, et al.
Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer: A Pooled Analysis
J. Clin. Oncol., May 15, 2004; 22(10): 1785 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gill, C. L. Loprinzi, D. J. Sargent, S. D. Thome, S. R. Alberts, D. G. Haller, J. Benedetti, G. Francini, L. E. Shepherd, J. Francois Seitz, et al.
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
J. Clin. Oncol., May 15, 2004; 22(10): 1797 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. M. Ribic, D. J. Sargent, M. J. Moore, S. N. Thibodeau, A. J. French, R. M. Goldberg, S. R. Hamilton, P. Laurent-Puig, R. Gryfe, L. E. Shepherd, et al.
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
N. Engl. J. Med., July 17, 2003; 349(3): 247 - 257.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Z. Ayanian, A. M. Zaslavsky, C. S. Fuchs, E. Guadagnoli, C. M. Creech, R. D. Cress, L. C. O'Connor, D. W. West, M. E. Allen, R. E. Wolf, et al.
Use of Adjuvant Chemotherapy and Radiation Therapy for Colorectal Cancer in a Population-Based Cohort
J. Clin. Oncol., April 1, 2003; 21(7): 1293 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. T. Arkenau, A. Bermann, K. Rettig, G. Strohmeyer, and R. Porschen
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial
Ann. Onc., March 1, 2003; 14(3): 395 - 399.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Iwashyna and E. B. Lamont
Effectiveness of Adjuvant Fluorouracil in Clinical Practice: A Population-Based Cohort Study of Elderly Patients With Stage III Colon Cancer
J. Clin. Oncol., October 1, 2002; 20(19): 3992 - 3998.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Schrag, S. Rifas-Shiman, L. Saltz, P. B. Bach, and C. B. Begg
Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer
J. Clin. Oncol., October 1, 2002; 20(19): 3999 - 4005.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren
Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy
J. Clin. Oncol., April 1, 2002; 20(7): 1721 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. Summerhayes
Capecitabine: a novel, orally administered, tumour-activated treatment for colorectal cancer
Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 107 - 125.
[Abstract] [PDF]

Home page
 NEJMHome page
D. J. Sargent, R. M. Goldberg, S. D. Jacobson, J. S. Macdonald, R. Labianca, D. G. Haller, L. E. Shepherd, J. F. Seitz, and G. Francini
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
N. Engl. J. Med., October 11, 2001; 345(15): 1091 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Schrag, L. D. Cramer, P. B. Bach, and C. B. Begg
Age and Adjuvant Chemotherapy Use After Surgery for Stage III Colon Cancer
J Natl Cancer Inst, June 6, 2001; 93(11): 850 - 857.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. C. Hodgson, C. S. Fuchs, and J. Z. Ayanian
Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer
J Natl Cancer Inst, April 4, 2001; 93(7): 501 - 515.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Porschen, A. Bermann, T. Loffler, G. Haack, K. Rettig, Y. Anger, and G. Strohmeyer
Fluorouracil Plus Leucovorin as Effective Adjuvant Chemotherapy in Curatively Resected Stage III Colon Cancer: Results of the Trial adjCCA-01
J. Clin. Oncol., March 15, 2001; 19(6): 1787 - 1794.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. Anthony, C. Jones, J. Antoine, S. Sivess-Franks, and R. Turnage
The Effect of Treatment for Colorectal Cancer on Long-Term Health-Related Quality of Life
Ann. Surg. Oncol., January 1, 2001; 8(1): 44 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
T. Mahoney, Y.-H. Kuo, A. Topilow, and J. Mihran Davis
Stage III Colon Cancers: Why Adjuvant Chemotherapy Is Not Offered to Elderly Patients
Arch Surg, February 1, 2000; 135(2): 182 - 185.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
O. W. Brawley and H. P. Freeman
Race and Outcomes: Is This the End of the Beginning for Minority Health Research?
J Natl Cancer Inst, November 17, 1999; 91(22): 1908 - 1909.
[Full Text] [PDF]

Home page
 JCOHome page
N. Wolmark, H. Rockette, E. Mamounas, J. Jones, S. Wieand, D.L. Wickerham, H. D. Bear, J. N. Atkins, N. V. Dimitrov, A. G. Glass, et al.
Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project C-04
J. Clin. Oncol., November 1, 1999; 17(11): 3553 - 3559.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. D. Recht and J. M. Primavera
Case 24-1999- Neurologic Disorder in a 65-Year-Old Man after Treatment of Colon Cancer
N. Engl. J. Med., August 12, 1999; 341(7): 512 - 519.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. C. Halling, A. J. French, S. K. McDonnell, L. J. Burgart, D. J. Schaid, B. J. Peterson, L. Moon-Tasson, M. R. Mahoney, D. J. Sargent, M. J. O'Connell, et al.
Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers
J Natl Cancer Inst, August 4, 1999; 91(15): 1295 - 1303.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. Summerhayes
Raltitrexed and the treatment of advanced colorectal cancer
Journal of Oncology Pharmacy Practice, December 1, 1996; 2(4): 225 - 235.
[Abstract] [PDF]

Home page
 BMJHome page
M. L Slevin
Author's reply
BMJ, June 1, 1996; 312(7043): 1417c - 1418.
[Full Text]

Home page
 BMJHome page
M. L Slevin
Adjuvant treatment for colorectal cancer
BMJ, February 17, 1996; 312(7028): 392 - 393.
[Full Text]

Home page
 The OncologistHome page
L. B. Saltz and N. E. Kemeny
Adjuvant Chemotherapy of Colorectal Cancer
Oncologist, February 1, 1996; 1(1): 22 - 29.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
P. Gilbar
A possible allergic reaction to levamisole
Journal of Oncology Pharmacy Practice, December 1, 1995; 1(4): 49 - 50.
[PDF]

Home page
 NEJMHome page
J. Jen, H. Kim, S. Piantadosi, Z.-F. Liu, R. C. Levitt, P. Sistonen, K. W. Kinzler, B. Vogelstein, and S. R. Hamilton
Allelic Loss of Chromosome 18q and Prognosis in Colorectal Cancer
N. Engl. J. Med., July 28, 1994; 331(4): 213 - 221.
[Abstract] [Full Text]

Home page
 NEJMHome page
M. Tempero and J. Anderson
Progress in Colon Cancer -- Do Molecular Markers Matter?
N. Engl. J. Med., July 28, 1994; 331(4): 267 - 268.
[Full Text]

Home page
 NEJMHome page
C. G. Moertel
Chemotherapy for Colorectal Cancer
N. Engl. J. Med., April 21, 1994; 330(16): 1136 - 1142.
[Full Text]

Home page
 Journal of Pharmacy PracticeHome page
J. M. Scholtz
General Principles and Pharmacology of Antineoplastic Agents
Journal of Pharmacy Practice, January 1, 1991; 4(1): 3 - 10.
[PDF]

Home page
 JWatch GeneralHome page
A NEW AGENT FOR COLON CANCER
Journal Watch (General), October 31, 1989; 1989(1031): 1 - 1.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 Site Map

Copyright © 1989 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online